Mochida's Research Center - targeting diabetes and obesity as its core fields and chronic pain as another important field of study - is immersed in efforts to discover and synthesize promising low-molecular weight compounds, using state-of-the-art computer-screening, high-throughput screening, and other advanced methods.
Mochida Pharmaceutical's product development pipelines offer lineups that will greatly enhance our major specialities: cardiovascular medicine, obstetrics and gynecology, dermatology, emergency medicine, and psychiatry. We remain ever committed to the efficient development of new and widely hoped-for therapeutic drugs, to be put to medical use as soon as is safely possible.
|MLD-55||escitalopram||Social anxiety disorder||Oral||Preparation for submission||Licensed-in from Lundbeck (Denmark)|
|MD-0901||mesalazine||Ulcerative colitis||Oral||Phase III||Licensed-in from Shire Pharmaceuticals Group
|MJR-35||dienogest||Uterine adenomyosis||Oral||Phase III||Licensed-in from Jenapharm (Bayer Pharma AG)|
|LBEC0101||etanercept||Rheumatoid arthritis||Injection||Preparation for Phase III||Biosimilar (Follow-on biologics)
Licensed-in from LG Life Sciences(Korea)
|MTD-39||imiquimod||common warts||Topical||Early Phase II||Licensed-in from iNova Pharmaceuticals|